Advertisement

European Journal of Clinical Pharmacology

, Volume 31, Issue 5, pp 519–524 | Cite as

The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients

  • K. R. Lees
  • J. L. Reid
Originals

Summary

We have studied the effects of treatment for one month with perindopril, 4 or 8 mg once daily, in seven hypertensive patients. Blood pressure was lowered from 164/93 mm Hg to 145/84 mm Hg by 4 mg of perindopril and after one month remained at 142/82 mm Hg. Neither postural hypotension nor tachycardia occurred.

Inhibition of plasma angiotensin converting enzyme (ACE) lasting for over 24 h was achieved and there was a significant increase in plasma renin activity (PRA).

Maximum plasma concentrations of the active metabolite of perindopril, S-9780, were detected four h after oral administration.

After treatment for one month there was evidence of reduced sensitivity of plasma ACE to the action of the inhibitor. The plasma concentration of S-9780 required to produce 50% inhibition of plasma ACE rose from 2.4 ng · ml−1 following the first dose to 5.5 ng · ml−1 after one month.

Key words

perindopril hypertension angiotensin converting enzyme inhibition renin-angiotensin system 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Laubie M, Schiavi P, Vincent M, Schmitt H (1984) Inhibition of angiotensin I-converting enzyme with S 9490: Biochemical effects, inter species differences, and role of sodium diet in haemodynamic effects. J Cardiovasc Pharmacol 6: 1076–1082Google Scholar
  2. 2.
    Lees KR, Reid JL (1984) Single and multiple administration of an angiotensin converting enzyme inhibitor, S-9490-3, in normotensive subjects. Br J Clin Pharmacol 19 [1]: 132–133Google Scholar
  3. 3.
    Lees KR, Reid JL (1985) Effects in normotensive subjects of perindopril, an angiotensin converting enzyme inhibitor. Clin Sci 69 [Suppl 12]: 49Google Scholar
  4. 4.
    Cushman DW, Cheung HS (1971) Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 20: 1637–1648Google Scholar
  5. 5.
    Chiknas SG (1979) A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum. Clin Chem 25 [7]: 1259–1262Google Scholar
  6. 6.
    Derkx FHM, Tan-Tjiong HL, Man in't Veld AJ, Schalekamp MBA, Schalekamp MADH (1979) Activation of inactive plasma renin by plasma and tissue kallikreins. Clin Sci 57: 351–357Google Scholar
  7. 7.
    McKenzie JK, Clements JA (1974) Simplified radioimmunossay for serum aldosterone utilising increased antibody specificity. J Clin Endocrinol Metab 38: 622–627Google Scholar
  8. 8.
    da Prada M, Zurcher G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci 19: 1161–1174Google Scholar
  9. 9.
    Tocco DJ, de Luna FA, Duncan AEW, Vassil TC, Ulm EH (1982) The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab Dispos 10 [1]: 15–19Google Scholar
  10. 10.
    Winer BJ (1971) Design and analysis of single factor experiments. In: Statistical principles in experimental design, 2nd edn, chapter 3. McGraw Hill, New York, pp 196–201Google Scholar
  11. 11.
    Ajayi AA, Lees KR, Reid JL (1986) Effects of angiotensin converting enzyme inhibitor, perindopril, on autonomic reflexes. Eur J Clin Pharmacol 30: 177–182Google Scholar
  12. 12.
    Case DV, Wallace JM, Keim HJ, Weber MA, Selaey JE, Laragh JH (1977) Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med 296: 641–646Google Scholar
  13. 13.
    DiNicolantonio R, Doyle AE (1985) Comparison of the actions of the angiotensin-converting enzyme inhibitors enalapril and S-9490-3 in sodium-deplete and sodium-replete spontaneously hypertensive rats. J Cardiovasc Pharmacol 7: 937–942Google Scholar
  14. 14.
    Man in't Veld AJ, Schicht IM, Derkx FHM, de Bruyn JHV, Schalekamp MADH (1980) Effect of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. Br Med J 1: 280–190Google Scholar
  15. 15.
    Millar JH, Derkx FHM, McLean K, Reid JL (1982) Pharmacodynamics of converting enzyme inhibition: The cardiovascular endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol 14: 347–355Google Scholar
  16. 16.
    Campbell BC, Sturani A, Reid JL (1985) Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man. Clin Sci 68 [1] 49–56Google Scholar
  17. 17.
    Sturani A, Chiarini C, Degli Esposti E, Santoro A, Zuccala A, Zuccelli C (1982) Heart rate control in hypertensive patients treated by captopril. Br J Clin Pharmacol 14: 849–855Google Scholar
  18. 18.
    Aldigier J, Plouin P, Guyene TT, Thibonnier M, Corvol P, Menard J (1982) Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension. Am J Cardiol 49: 1447–1452Google Scholar
  19. 19.
    Weidemann P, de Myttenaere-Bursztein S, Maxwell MH, de Lima J (1975) Effects of aging on plasma renin and aldosterone in normal man. Kidney Intern 8: 325–333Google Scholar
  20. 20.
    Weber B, Brunner HR, Brunner DB, Curtet A, Turini GA, Gavras H (1980) Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 2: 236–242Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • K. R. Lees
    • 1
  • J. L. Reid
    • 1
  1. 1.University Department of Materia MedicaStobhill General HospitalGlasgowUK

Personalised recommendations